New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) - modified release tablet - 12 mg - active: paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega prolonged release tablet is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) - modified release tablet - 3 mg - active: paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) excipient: butylated hydroxytoluene carnauba wax cellulose acetate glycerol hyetellose hypromellose iron oxide red iron oxide yellow lactose macrogol 3350 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) - modified release tablet - 6 mg - active: paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 9mg (drug layer 1: 2.7 mg, drug layer 2: 6.3 mg) - modified release tablet - 9 mg - active: paliperidone 9mg (drug layer 1: 2.7 mg, drug layer 2: 6.3 mg) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide black iron oxide red macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega prolonged release tablet is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 16mg (+ 9% overage to account for residual drug retained in capsule shell) - modified release tablet - 16 mg - active: hydromorphone hydrochloride 16mg (+ 9% overage to account for residual drug retained in capsule shell) excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry yellow y-30-12863-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 32mg - modified release tablet - 32 mg - active: hydromorphone hydrochloride 32mg excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black iron oxide yellow macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry white y-30-18037 polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 4mg (+ 9% system overage) - modified release tablet - 4 mg - active: hydromorphone hydrochloride 4mg (+ 9% system overage) excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black iron oxide yellow macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 64mg - modified release tablet - 64 mg - active: hydromorphone hydrochloride 64mg excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry blue y-30-10701 opadry clear ys-1-19025-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 8mg (+ 9% overage to account for residual drug retained in capsule shell) - modified release tablet - 8 mg - active: hydromorphone hydrochloride 8mg (+ 9% overage to account for residual drug retained in capsule shell) excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry red y-30-15595-a polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ketoconazole 200mg - tablet - 200 mg - active: ketoconazole 200mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone